Tislelizumab efficacy and safety compared to other anti–PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
Tislelizumab + CT is an effective 1L treatment option for advanced or metastatic ESCC, demonstrating comparable efficacy and safety outcomes relative to existing treatments.
Authors
- Emily Prentiss
- JeanPierre Coaquira Castro (ORCID: https://orcid.org/0000-0002-0140-1848)
- Wenxi Tang (ORCID: https://orcid.org/0000-0002-2918-0434)
- Jaffer A. Ajani (ORCID: https://orcid.org/0000-0001-9946-0629)
- K Szafranski
- Jason Steenkamp
- Hyun Ae Jung
- Elizabeth Smyth
- David Tougeron
- Lin Zhan
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Samsung Medical Center (KR)
- Université de Poitiers (FR)
- Oxford University Hospitals NHS Trust (GB)
- Universidad San Carlos (PY)
- EVERSANA (Canada) (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1657085
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00